Back to search

Article

Optimal control of Multiple Myeloma assuming drug evasion and off-target effects

2024-06-09

Abstract excerpt

Multiple Myeloma (MM) is a plasma cell cancer that occurs in the bone marrow. A leading treatment for MM is the monoclonal antibody Daratumumab, targeting the CD38 receptor, which is highly overexpressed in myeloma cells. In this work we model drug evasion via loss of CD38 expression, which is a proposed mechanism of resistance to Daratumumab treatment. We develop an ODE model that includes drug evasion via two me...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c4b8dc2b-2ead-5560-884d-4ebccb31b270
DOI
10.1101/2024.06.06.597698
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Optimal control of Multiple Myeloma assuming drug evasion and off-target effectsDOI 10.1101/2024.06.06.597698
A computational model of MGUS progression to Multiple Myeloma identifies optimum screening strategies and their effects on mortalitySemantic proximity
Personalized Immunotherapy via Multiscale Tumor-Immune Modeling and Optimal ControlSemantic proximity
The ecology of cancer from an evolutionary game theory perspectiveSemantic proximity
Impact of Daratumumab in Transplant Eligible/Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Meta-Analysis of Phase- III TrialsSemantic proximity
Impact of Resistance on Therapeutic Design: A Moran Model of Cancer GrowthSemantic proximity
Understanding the potential benefits of adaptive therapy for metastatic melanomaSemantic proximity
Threshold-awareness in adaptive cancer therapySemantic proximity
Deriving Optimal Treatment Timing for Adaptive Therapy: Matching the Model to the Tumor DynamicsSemantic proximity
Mitigating non-genetic resistance to checkpoint inhibition based on multiple states of immune exhaustionSemantic proximity
Drug resistance in cancer: Principles of emergence and preventionSemantic proximity
A fractional-order model for optimizing combination therapy in heterogeneous lung cancer: integrating immunotherapy and targeted therapy to minimize side effects.Semantic proximity
Mechanisms of Resistance to CAR-T cell Immunotherapy: Insights from a Mathematical ModelSemantic proximity
Select a neighboring publication to make it the new centre.